Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Fasedienol Nasal Spray Reduces Anxiety Symptoms in Patients with SAD

The double-blind, placebo-controlled trial included 141 participants, with 70 receiving fasedienol and 71 receiving a placebo.

The phase 3 PALISADE-2 trial has recently evaluated the efficacy of fasedienol nasal spray, a first-in-class, rapid-onset investigational treatment, in adults diagnosed with social anxiety disorder (SAD). The study’s findings reveal promising results in reducing anxiety symptoms, particularly during public speaking challenges.

Key Points:

  • The primary endpoint was the difference in Subjective Units of Distress Scale (SUDS) score during a public speaking challenge.
  • Treatment with fasedienol showed a statistically significant difference in average SUDS score compared to placebo (difference of -5.8; P =.015).
  • 37.7% of fasedienol-treated patients were rated as responders, compared to 21.4% of placebo recipients (P =.033).
  • The treatment was reported to have a favorable safety profile.

Additional Points:

  • The trial has been stopped due to business reasons, with further analysis of the data ongoing.
  • A future phase 3 study will explore multiple administrations of fasedienol over several weeks.


  • Fasedienol nasal spray has demonstrated potential as an effective treatment for SAD, with significant reductions in anxiety symptoms and a favorable safety profile.

Related Posts

“Fasedienol demonstrated a rapid and very clinically meaningful reduction in SUDS score, indicating a single administration has the potential to reduce anxiety symptoms during an anxiety-provoking situation.”

Dr. Michael R. Liebowitz
Innovator of the LSAS
Managing Director
The Medical Research Network LLC
New York, NY
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form